A Rare Case of Pneumocystis Pneumonia in HIV Patient on Glucocorticoid

Usama Rehman 1, Khawlah Farhan 2, Warda Shahnawaz 3, Muhammad Zain Khalid 4, Karun Neupane 5

1. Anaesthesia, Mayo Hospital, Lahore, PAK 2. Internal Medicine, Zhejiang University, Hangzhou, CHN 3. Medicine, Jinnah Sindh Medical University, Karachi, PAK 4. Neurology, Liaquat National Hospital and Medical College, Karachi, PAK 5. Internal Medicine, Manipal College of Medical Sciences, Pokhara, NPL

Corresponding author: Khawlah Farhan, khawla6k6k@gmail.com

Abstract

Pneumocystis pneumonia (PCP) is an opportunistic infection caused by Pneumocystis jirovecii. PCP due to immunosuppressive drugs is rarely reported in the literature. Herein we present a case of PCP in a 49-year-old patient who presented with progressive shortness of breath, dry cough, and low-grade fever. History revealed that he was taking prednisolone daily for his hyperactive airway disease. His temperature was $99^\circ F$, and he had bilateral crackles in the lungs with resonant wheezing. High-resolution computed tomography showed diffuse ground-glass haze and cystic lesions in the middle and upper zones of both lungs. He was commenced on intravenous ceftriaxone and methylprednisolone based on provisional diagnosis of interstitial pneumonia. However, his condition worsened. His human immunodeficiency virus (HIV) test was reactive, and his CD4+ count was 275 cells/mm$^3$. Bronchoalveolar lavage revealed PCP by direct immunofluorescent assay. Additional serum testing revealed marked elevation of beta-D-glucan, consistent with PCP diagnosis due to glucocorticoid use. Trimethoprim-sulfamethoxazole and voriconazole were initiated, and his respiratory symptoms started improving. His respiratory condition improved on day 9, and he was discharged with follow-up.

Introduction

Pneumocystis pneumonia (PCP) is an opportunistic infection caused by Pneumocystis jirovecii in immunocompromised patients, such as acquired immunodeficiency syndrome (AIDS), underlying hematologic malignancy, organ transplantation, chronic inflammatory conditions, and patients on immunosuppressive drugs [1]. It emerged at the beginning of the AIDS pandemic in 1981. A low CD4+ lymphocyte count of fewer than 200 cells/mm$^3$ is a risk factor for PCP development and has become the most severe complication of the human immunodeficiency virus (HIV). However, it remains the most frequent AIDS-defining illness in the United States [2]. PCP due to immunosuppressive drugs is rarely reported in the literature [3]. Herein we present a case of PCP in HIV patient due to inappropriate use of glucocorticoids.

Case Presentation

A 49-year-old male with a past medical history of hypertension and diabetes mellitus presented with progressive shortness of breath for the last two weeks. He complained of fatigue, dry cough, and low-grade fever for the last 10 days. He had hospitalization due to a road traffic accident six months back. He was homosexual and had two male partners in the last year. His HIV antibody test was negative six months back. His history of occupational exposure or environmental hazards was unremarkable. Further history revealed that he took 20 mg prednisolone daily for his hyperactive airway disease for the last two months. He was diagnosed with community-acquired pneumonia in his local hospital and treated with intravenous ceftriaxone; however, his condition did not improve.

On examination, he had a temperature of $100^\circ F$, blood pressure of 110/75 mmHg, heart rate of 80 per minute, respiratory rate of 27/minute, and oxygen saturation of 95% on room air. On auscultation, he had bilateral crackles in the lungs with resonant wheezing throughout the respiration. Rest of the physical exam, including cardiovascular system and abdomen, was normal. Initial laboratory investigations revealed an elevated erythrocyte sedimentation rate (Table 1).
| Parameter          | Lab value                              | Reference range   |
|--------------------|----------------------------------------|-------------------|
| WBC                | 6,171/mm$^3$, neutrophil 58.2%, lymphocyte 34.3% | 4,000-11,000      |
| Platelets          | 301,000/mm$^3$                         | 150,000-350,000   |
| Hemoglobin         | 13.1 g/dL                              | 14-17             |
| ALT                | 31 IU/L                                | < 35              |
| AST                | 36 IU/L                                | < 35              |
| Serum albumin      | 3.2 g/dL                               | 4-5               |
| Sodium             | 135 mmol/L                             | 136-145           |
| Potassium          | 3.7 mmol/L                             | 3.5-5.0           |
| Calcium            | 8.9 mg/dL                              | 8.5-10.5          |
| Creatinine         | 0.8 mg/dL                              | 0.7-1.2           |
| Blood urea nitrogen| 13 mg/dL                               | 8-20              |
| ESR                | 35                                     | < 22              |
| CRP                | 11 mg/dL                               | < 0.2             |
| LDH                | 401 IU/L                               | 119-229           |

**TABLE 1: Initial blood work-up.**

WBC; white blood cell, ALT; alanine aminotransferase, AST; aspartate aminotransferase, ESR; erythrocyte sedimentation rate, CRP; C-reactive protein, LDH; lactate dehydrogenase.

Chest x-ray revealed diffuse alveolar infiltration in both lungs (Figure 1). High-resolution computed tomography (HRCT) was performed, which showed diffuse ground-glass haze in both lung fields along with bronchiectatic changes predominantly in the mid zones. Multiple cystic lesions were also noted, mainly in the middle and upper zones of both lungs, some of which were coalescing together. Fine reticulation was also noted bilaterally (Figure 2). Initially, he was commenced on intravenous ceftriaxone and prednisolone based on the provisional diagnosis of interstitial pneumonia.
FIGURE 1: Chest x-ray showing diffuse infiltrates in both lung fields.
On the fourth day of admission, his condition worsened, and oxygen saturation did not improve. His blood and sputum culture were negative for any organisms. Due to the high risk of contracting HIV and the nature of the illness, he underwent HIV testing. His enzyme-linked immunosorbent assay (ELISA) was reactive, and western blot was positive. His CD4+ lymphocyte count was 275 cells/mm$^3$. Bronchoscopy was performed, and bronchoalveolar lavage revealed PCP by direct immunofluorescent assay. Additional serum testing revealed marked elevation of β-D-glucan (BG) of 67 pg/ml, consistent with a diagnosis of PCP due to glucocorticoid use as CD4+ count was more than 200 cells/mm$^3$. Trimethoprim-sulfamethoxazole (TMP-SMX) and voriconazole were initiated, and his respiratory symptoms started improving. His respiratory condition improved on day 9, and he was discharged. On follow-up after three weeks, he was doing well without recurrence of respiratory problems or evidence of immune restoration inflammatory syndrome. C-reactive protein and BG were within the normal range. His repeat HIV antibody was reactive and was commenced on antiretroviral therapy.

**Discussion**

*Pneumocystis jirovecii*, previously called *Pneumocystis carinii*, affects immunocompromised patients and can be fatal in some cases [4]. Patients with an underlying disease that affect the host immune response are at high risk of contracting the disease. PCP is a fatal infection inducing inflammatory response and accumulation of fluid in the lungs leading to respiratory manifestations [5]. Although infection is rare, it spreads through the air, and in severe cases, PCP can involve other parts of the body, including the liver, bone marrow, and lymph node [1]. In immunocompromised patients, two-thirds of the cases occur in HIV patients. One-third occurs in patients who have a malignant disease, chronic inflammatory conditions, or patients on immunosuppressive drugs. The role of corticosteroids among immunosuppressive agents is prominent, and many reasons have been implicated in increased susceptibility of PCP in these patients [6,7]. One of the proposed explanations is deficient cell-mediated immunity and decreased CD4+ lymphocytes. The patient can also have associated signs and symptoms such as fatigue, headache, rash, and myalgia.

PCP usually presents with subclinical infection or obvious signs of illness. Presenting patients can have a low-grade fever, dyspnea, productive cough over several weeks. Patients typically have respiratory distress and some degree of hypoxemia while presenting in the hospital. Detailed history regarding any immunodeficiency and drug history is pertinent for appropriate clinical diagnosis of PCP [1]. Diagnosis is multifactorial and requires a multidisciplinary approach. Clinical suspicion, risk factors, laboratory
investigations, imaging modalities, sputum studies, and invasive lung studies can help diagnosis. Lab workup can be non-specific, and elevated LDH and BG can be identified in the serum of the infected patients. The chest x-ray can reveal diffuse interstitial infiltrates, solitary or multiple nodules leading to cystic and cavitory lesions [8]. CT chest should be obtained for cystic lesions or ground-glass attenuation. For a definitive diagnosis of PCP, polymerase chain reaction (PCR) of respiratory specimens or fluorescein antibody staining is required [6].

Management of PCP requires early diagnosis and treatment with TMP-SMX. For mild to moderate treatment, oral treatment should be initiated, and for severe cases, intravenous TMP-SMX should be commenced [9]. Alternative therapies include atovaquone, trimethoprim, dapsone, primaquine, or clindamycin [1]. Glucocorticoids can be added to HIV-induced PCP. Prophylactic treatment is recommended for immunocompromised patients, such as those taking glucocorticoids, bone marrow suppressive therapies, or antineoplastic therapies [10]. The patient outcome depends on age, comorbidities, degree of hypoxia at presentation, other opportunistic infections, and low CD4+ count, resulting in poor outcome and mortality.

Our patient presented with non-specific clinical signs and symptoms. History of improper steroid use, lymphocytopenia, and cavitory and cystic lesion on HRCT led to the diagnosis of PCP. A strong clinical suspicion and early diagnosis and management led to the recovery of the patient.

**Conclusions**

Although PCP infection is rare; however, it should be considered in the differential diagnosis of pneumonia in immunocompromised patients presenting with non-specific respiratory symptoms, lymphocytopenia. A precise and detailed history and a thorough examination is a fundamental key to diagnosis. Clinical and microbiological evaluations are indicated in high-risk patients, and BG can help diagnose PCP. Early diagnosis and management with TMP-SMZ can result in a better prognosis for the patient.

**Additional Information**

**Disclosures**

**Human subjects:** Consent was obtained or waived by all participants in this study. NA issued approval NA. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

**References**

1. Truong J, Ashurst JV: Pneumocystis jirovecii pneumonia. StatPearls. StatPearls Publishing, Treasure Island, FL; 2021.
2. Huang L, Crothers K: HIV-associated opportunistic pneumonias. Respiriology. 2009, 14:474–85. 10.1111/j.1440-1843.2009.01534.x
3. Tabarsi P, Mirsaedi M, Amir M, Karimi S, Masjedi MR, Mansouri D: Inappropriate use of steroid and pneumocystis jiroveci pneumonia: report of two cases. East Mediterr Health J. 2008, 14:1217–21.
4. Lee YT, Chuang ML: Pneumocystis jiroveci pneumonia in AIDS and non-AIDS immunocompromised patients – an update. J Infect Dev Ctries. 2018, 12:844–54. 10.3855/jidc.10537
5. Ricciardi A, Gentilotti E, Coppola L, et al.: Infectious disease ward admission positively influences P. jiroveci pneumonia (PJP) outcome: a retrospective analysis of 116 HIV-positive and HIV-negative immunocompromised patients. PLoS One. 2017, 12:e0176881. 10.1371/journal.pone.0176881
6. Sepkowitz KA, Brown AE, Telzak EE, et al.: Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. JAMA. 1992, 267:852–7.
7. Yale SH, Limper AH: Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc. 1996, 71:5-13. 10.4065/71.1.5
8. Langevin B, Saleh M: Radiological presentation of pneumocystis jirovecii pneumonia mimicking bacterial pneumonia. BMJ Case Rep. 2016, 2016:6.bcr2016215207. 10.1136/bcr-2016-215207
9. Liebling M, Rubio E, Le S: Prophylaxis for pneumocystis jiroveci pneumonia: is it a necessity in pulmonary patients on high-dose, chronic corticosteroid therapy without AIDS? Expert Rev Respir Med. 2015, 9:171-81. 10.1586/17446998.2015.1002471
10. Newberry L, O’Hare B, Kennedy N, et al.: Early use of corticosteroids in infants with a clinical diagnosis of pneumocystis jiroveci pneumonia in Malawi: a double-blind, randomised clinical trial. Paediatr Int Child Health. 2017, 37:121–8. 10.1080/20469047.2016.1260891